At a glance
- Originator Novartis
- Class Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 22 Jan 2001 No-Development-Reported for Cancer in Germany (Unknown route)
- 22 Jan 2001 No-Development-Reported for Cancer in United Kingdom (Unknown route)